What are the common side effects after taking Larotrectinib?

Larotrectinib is an oral, selective NTRK fusion protein inhibitor, mainly used to treat solid tumors carrying NTRK gene fusions. As a targeted therapy drug, larotinib can significantly improve the patient's condition, but it is also accompanied by certain adverse reactions. Understanding and identifying these common side effects can help patients and doctors manage them in a timely manner to ensure the safety and effectiveness of treatment. The following will introduce in detail the common side effects and manifestations of larotrectinib from many aspects.

First, the neurological side effects of larotrectinib are more prominent. Patients may experience symptoms such as headache, dizziness, abnormal sensation (such as numbness or tingling), and fatigue during medication. Some patients also experience mild cognitive impairment, such as decreased concentration or memory loss, often due to the drug's effects on the nervous system. Nervous system adverse reactions are generally mild to moderate, mostly short-lived, and most patients' symptoms can be relieved after dose adjustment or symptomatic treatment. However, if you experience severe dizziness or unconsciousness, you should seek medical attention immediately to check for other potential risks.

Secondly, digestive system discomfort is also one of the common side effects of larotrectinib. Patients may experience nausea, vomiting, diarrhea, or constipation. Some patients may experience loss of appetite, leading to weight loss. In order to reduce the side effects of the digestive system, patients are advised to eat small and frequent meals, eat a light and easy-to-digest diet, and avoid greasy and irritating foods. If the symptoms are obvious, antiemetics or drugs to regulate intestinal function can be used under the guidance of a doctor. Prompt treatment of gastrointestinal discomfort not only improves patients' quality of life but also promotes medication compliance.

Third, larotrectinib may cause blood system abnormalities. Some patients may develop mild anemia, leukopenia or thrombocytopenia during treatment. Most of these side effects are reversible, and regular blood tests can help early detection and intervention. Once hematological indicators are abnormal, doctors may recommend temporarily stopping the drug or adjusting the dose to prevent serious complications such as infection and bleeding. During treatment, patients should pay attention to observe whether there are any symptoms of fatigue, bleeding tendency or infection, and report to the doctor in time.

In addition, skin reactions are also common side effects during the use of larotrectinib. People may develop a rash, itching, or dry skin, sometimes with mild redness and swelling. Although most skin reactions are mild, some patients may need antihistamines or topical skin care products to relieve symptoms. Keeping your skin clean and moisturized and avoiding excessive sun exposure and irritation can reduce the occurrence of discomfort.

In addition to the above-mentioned common side effects, larotrectinib may occasionally cause abnormal liver function, manifested as elevated transaminases, etc. Impaired liver function usually has no obvious symptoms and needs to be detected through regular liver function tests. If liver enzymes are found to be significantly elevated, doctors will adjust the medication regimen or suspend treatment according to the specific situation to prevent further liver damage. In addition, some patients may experience heart-related side effects such as prolonged electrocardiogram QT interval, and cardiac monitoring is required before and during treatment.

In summary, although larotrectinib is an innovative targeted therapy drug with remarkable efficacy, patients may still experience various side effects such as nervous system reactions, digestive system discomfort, hematological abnormalities, and skin reactions while taking it. Through standardized monitoring and timely symptomatic treatment, most side effects can be effectively controlled. Patients should maintain close communication with their doctors, follow the doctor's instructions for regular check-ups, and provide timely feedback when experiencing discomfort, so as to ensure the smooth progress of treatment and good health.

Reference materials:https://www.vitrakvi.com/